Retosiban

From Food & Medicine Encyclopedia

Retosiban


Retosiban is a drug that is classified as an oxytocin receptor antagonist. It was developed by GlaxoSmithKline for the management of preterm labor.

History[edit]

Retosiban was first synthesized by GlaxoSmithKline in the early 21st century. The drug was developed as a potential treatment for preterm labor, a condition that affects approximately 10% of all pregnancies worldwide.

Mechanism of Action[edit]

Retosiban works by blocking the action of oxytocin, a hormone that stimulates uterine contractions. By inhibiting the oxytocin receptor, Retosiban can potentially delay or prevent the onset of labor.

Clinical Trials[edit]

Several clinical trials have been conducted to evaluate the safety and efficacy of Retosiban. In Phase II trials, the drug was found to be well-tolerated and showed promising results in delaying preterm labor. However, further studies are needed to confirm these findings and to determine the optimal dosing regimen.

Potential Applications[edit]

In addition to its potential use in preterm labor, Retosiban may also have applications in other conditions that involve oxytocin, such as postpartum hemorrhage, dysmenorrhea, and certain psychiatric disorders.

See Also[edit]

This article is a stub related to pharmacology. You can help WikiMD by expanding it!


Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.